Attorney General Phil Weiser announces $29.6 million settlement with Glenmark over conspiracy to inflate generic drug prices

Attorney General Phil Weiser announces $29.6 million settlement with Glenmark over conspiracy to inflate generic drug prices

July 15, 2026 (DENVER) - Attorney General Phil Weiser today joined a bipartisan coalition of 48 states and territories in announcing a $29.6 million settlement with Glenmark Pharmaceuticals to resolve allegations that the generic drug manufacturer participated in a widespread, long-running conspiracy to inflate prices, reduce competition, and restrain trade for numerous generic prescription drugs.

Under the settlement, Colorado's estimated share is $406,518. Glenmark also agreed to cooperate in the ongoing multistate litigation against 33 corporate defendants and 25 individual executives and to implement internal reforms designed to strengthen compliance with antitrust laws and promote fair competition.

Today's announcement builds on settlements reached with Heritage and Apotex in 2024 and Lannett and Bausch earlier this year, bringing total settlements in the multistate litigation to $66.95 million. The states' antitrust cases against the remaining defendants are ongoing, with the first trial expected to begin in 2027.

"Generic drugs are supposed to make health care more affordable through competition, not become the subject of illegal price-fixing schemes," said Attorney General Weiser. "When companies conspire to manipulate prices, Colorado families, businesses, and public health programs all pay the price. This settlement holds Glenmark accountable, advances our ongoing case against other defendants, and reinforces that companies must compete fairly and follow the law."

Consumers who purchased generic prescription drugs manufactured by Glenmark, Lannett, Bausch, Apotex, or Heritage between May 2009 and December 2019 may be eligible for compensation. To learn more or determine eligibility, visit https://www.AGGenericDrugs.com (opens new tab), call 1-866-290-0182 (toll-free), or email [email protected].

Today's settlement is part of a series of multistate antitrust lawsuits against generic drug manufacturers and executives accused of conspiring to inflate prices and suppress competition. According to the states' complaints, competing executives coordinated through industry dinners, golf outings, phone calls, emails, and text messages, using terms such as "fair share" and "playing nice in the sandbox" to describe agreements that allegedly discouraged competition and kept prices artificially high.

States and territories participating in today's settlement with Glenmark include Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and Puerto Rico.

Read the settlement (PDF).

###

Media Contact:
Lawrence Pacheco
Chief Communications Officer
(720) 508-6553 office
[email protected]